Over the past decade, we have learned much about the problems associated with acute brain dysfunction during critical illness; currently, awareness of the ubiquitous presence of intensive care unit (ICU) delirium is growing. Th e paper by Pandharipande and colleagues [1] in the previous issue of Critical Care adds insight into this complex area. In 2004, Ely and colleagues [2] published groundbreaking work that identifi ed ICU delirium as an event occurring in over 80% of mechanically ventilated patients; those with ICU delirium had a threefold higher independent mortality risk compared with those who never had ICU delirium. Over the last 10 years, this group of investigators has worked extensively in the development and validation of the confusion assessment method for the ICU (CAM-ICU) to detect and better understand ICU delirium. According to this tool, delirium is defi ned as an acute change or fl uctuation in the course of mental status, plus inattention and either disorganized thinking or an altered level of consciousness [3] . Th e CAM-ICU tool uses the Richmond AgitationSedation Scale (RASS) to measure arousal [4] . Patients who are deeply unresponsive are categorized as comatose rather than delirious; that is, they respond only to physical/painful stimulation by moving but do not open their eyes (RASS score of −4) or have no response to verbal or physical stimulation (RASS score of −5). Patients who are neither delirious nor comatose are categorized as normal. Although coma and delirium are diff erent conditions, both can be placed in a category of acute brain dysfunction.
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Delirium (like acute brain dysfunction, for that matter) is not a disease but a syndrome with a wide spectrum of possible etiologies. Over the last few years, we have learned that ICU delirium does not come as a 'one size fi ts all' event. Rather, it appears that the longer [5] and more severe [6] the delirium is, the worse the patient outcomes are.
As reported in the previous issue of Critical Care, Pandharipande and colleagues [1] use data from the MENDS (maximizing effi cacy of targeted sedation and reducing neurological dysfunction) trial, which compared dexmedetomidine with lorazepam for ICU sedation in a randomized double-blinded fashion [7] . Sixty-one percent of patients (61/103) in the MENDS trial were admitted with sepsis. In this important post hoc analysis of these septic patients, dexmedetomidine-sedated patients had more delirium/coma-free days, deliriumfree days, and ventilator-free days and a lower 28-day mortality rate when compared with lorazepam-sedated patients [1] . It is important to realize that the randomization scheme for the MENDS trial was to dexmedetomidine versus lorazepam, not septic versus non-septic. Accordingly, the authors conclude (appropriately) that prospective clinical studies and further mechanistic preclinical studies are needed to confi rm these preliminary obser vational results. Acute brain dysfunction is common in patients with sepsis. Th e mechanisms by which such brain dysfunction occurs are not fully understood, but disturbances in infl ammation and coagulation pathways leading to micro vascular thrombosis are thought to be partly responsible. Th e commonplace administration of seda tives during mechanical ventilation of septic patients adds an additional layer of complexity to understanding acute brain dysfunction in these patients. As noted by Pandharipande and colleagues [1] , there is some evidence that benzodiazepines and alpha-2 adrenoceptor agonists exert opposing eff ects on the immune system. So it stands to reason that dexmedetomidine may be more effi cacious than lorazepam with regard to acute brain dysfunction in patients with sepsis.
As is the case in most well-designed trials, these results produce as many questions as they do answers. For example, in septic patients, how does one tease apart the impact of dexmedetomidine (compared with lorazepam) on sedation itself from the putative benefi ts of dex medetomidine on immune modulation, apoptosis, and so on?
How does the timing of the CAM-ICU delirium assessment impact the fi ndings in this study? Given the pharmacokinetic/dynamic properties of dexmedetomidine and lorazepam, whatever component of recovery from delirium or coma (or both) that is purely sedativerelated is likely to occur over diff ering time intervals when these two drugs are compared (that is, slower recovery and longer delirium/coma with lorazepam). Since the multicenter MENDS trial did not mandate one particular sedation algorithm, it may be that lingering eff ects of lorazepam may have aff ected the CAM-ICU delirium or coma assessments (or both) more in the dexmedetomidine group.
Th e distinction between delirium and coma in the CAM-ICU tool is logical but arbitrary. As a person transitions from a RASS score of −3 (opens the eyes or moves in response to voice but does not make eye contact) to −4 (responds only to physical/painful stimulation by moving but does not open the eyes), the term coma, rather than delirium, is used. With regard to acute brain dysfunction, is the delirium-to-coma transition merely a continuum of progressively lesser degrees of arousal, or is there a fundamental change in the pathophysiology of the acute brain dysfunction with this transition? Th ese questions remain unanswered at present.
Th e paper by Pandharipande and colleagues is an important advance in our understanding of the complex interconnections between acute brain dysfunction, sedation, and sepsis. However, we need further progress in our understanding of the complex pathophysiology of acute brain dysfunction in critically ill patients who require mechanical ventilation. Th is hypothesis-generating study lays important groundwork for future investigations of sepsis and sedation in this area.
